We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Sanofi-Aventis Czech Republic

Pharmaceutical > Czech Republic > Sanofi-Aventis Czech Republic
Change Company
Sanofi-Aventis Czech Republic

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo,

Read more »
Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines.

Buy all financials of Sanofi-Aventis Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
              7,040 7,225 6,531 6,120 6,596    
              536 574 605 485 693    
              82.9 71.4 89.3 9.99 89.5    
              55.1 45.2 65.2 1.19 58.6    
              11.0% 8.21% 10.8% 0.186% 8.76%    
              1.18% 0.988% 1.37% 0.163% 1.36%    
              0.782% 0.626% 0.998% 0.019% 0.889%    
              297 377 371 373 415    

balance sheet

              3,167 3,297 2,694 2,348 2,635    
              46.9 51.1 45.0 36.7 34.3    
              3,102 3,237 2,644 2,307 2,597    
              528 574 639 640 699    
              2,639 2,724 2,055 1,708 1,937    
              169 121 0.000 0.000 0.000    
              2,470 2,603 1,887 1,602 1,838    
              12.8 16.5 8.87 27.7 4.27    
              221% 232% 137% 73.7% 57.8%    
...             1.59% 1.50% 0.956% 1.24% 0.511%    

cash flow

              58.5 -155 460 404 70.6    
              -9.97 -13.5 -3.03 1.31 -2.71    
              -99.4 245 0.000 0.000 -67.1    
              -50.8 77.1 457 405 0.726    

Download Data
income statement Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
              7,040 7,225 6,531 6,120 6,596    
              6,505 6,651 5,927 5,635 5,903    
              536 574 605 485 693    
              334 427 433 427 509    
              111 66.7 72.1 41.6 89.5    
              90.8 80.9 98.9 17.0 94.6    
              7.90 9.55 9.60 7.04 5.12    
              82.9 71.4 89.3 9.99 89.5    
              19.3 19.3 11.0 8.40 2.24    
              0.000 0.000 0.000 0.000 0.000    
              63.6 52.0 78.4 1.59 87.2    
              8.55 6.81 13.2 0.401 28.6    
              0.000 0.000 0.000 0.000 0.000    
              55.1 45.2 65.2 1.19 58.6    

growth rates

...             -6.44% 2.62% -9.60% -6.30% 7.77%    
...             2.80% 10.9% 2.48% -7.42% 27.8%    
...             26.7% -10.9% 22.2% -82.8% 455%    
...             29.9% -13.9% 25.2% -88.8% 796%    
...             51.8% -18.2% 50.6% -98.0% 5,393%    
...             18.2% -17.9% 44.2% -98.2% 4,839%    

ratios

              11.0% 8.21% 10.8% 0.186% 8.76%    
...             2.97% 2.37% 3.65% 0.083% 4.39%    
              7.61% 7.95% 9.26% 7.93% 10.5%    
              1.29% 1.12% 1.51% 0.278% 1.43%    
              1.18% 0.988% 1.37% 0.163% 1.36%    
              0.782% 0.626% 0.998% 0.019% 0.889%    
...             1.59% 1.50% 0.956% 1.24% 0.511%    
              12.8 16.5 8.87 27.7 4.27    

Download Data
balance sheet Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

              46.9 51.1 45.0 36.7 34.3    
              39.6 45.3 40.4 35.4 34.0    
              5.90 4.39 3.12 1.30 0.328    
              3,102 3,237 2,644 2,307 2,597    
              1,347 1,415 1,182 1,028 1,294    
              1,573 1,506 1,293 1,112 1,302    
              0.106 77.2 5.67 0.065 0.791    
              3,167 3,297 2,694 2,348 2,635    
              528 574 639 640 699    
              0.000 0.000 0.000 0.000 0.000    
              2,639 2,724 2,055 1,708 1,937    
              169 121 0.000 0.000 0.000    
              0.000 0.000 0.000 0.000 0.000    
              0.000 0.000 0.000 0.000 0.000    
              2,470 2,603 1,887 1,602 1,838    
              1,165 1,410 883 471 404    
              1,094 1,033 887 963 1,176    
              68.7 67.5 53.8 52.6 99.1    
              3,167 3,297 2,694 2,348 2,635    

growth rates

...             1.84% 4.11% -18.3% -12.8% 12.2%    
...             11.6% 8.56% 11.4% 0.186% 9.16%    
...             -4.00% 14.4% -34.2% -46.3% -14.4%    
...             -7.86% 21.0% -37.4% -46.6% -14.2%    

ratios

              1,165 1,410 883 471 404    
              1,165 1,333 877 471 404    
              1,826 1,888 1,588 1,177 1,420    
              1,873 1,939 1,633 1,214 1,454    
              221% 232% 137% 73.7% 57.8%    
...             1.59% 1.50% 0.956% 1.24% 0.511%    

Download Data
cash flow Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

              55.1 45.2 65.2 1.19 58.6    
              7.90 9.55 9.60 7.04 5.12    
...             31.3 -148 86.0 -15.6 249    
...             -35.8 -61.9 299 411 -243    
              58.5 -155 460 404 70.6    
              -10.1 -13.6 -3.17 1.20 -2.77    
              0.139 0.061 0.137 0.113 0.061    
              -9.97 -13.5 -3.03 1.31 -2.71    
...             -99.4 245 -527 -412 -67.1    
              -99.4 245 0.000 0.000 -67.1    
              -50.8 77.1 457 405 0.726    

ratios

              81.5 76.1 72.3 66.3 72.1    
              75.6 77.6 72.8 66.6 80.0    
              61.4 56.7 54.6 62.4 72.7    
              95.7 97.0 90.4 70.6 79.3    
              63.0 54.8 74.8 8.23 63.7    
              48.5 -168 457 405 67.8    

Download Data
other data Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

              1.75% 1.40% 2.18% 0.047% 2.35%    
              7.61% 7.95% 9.26% 7.93% 10.5%    
              297 377 371 373 415    
              5,298 4,822 4,976 4,458 4,280    
              93,703 94,321 97,365 95,287 102,155    
              4.80% 5.96% 6.73% 6.98% 7.82%    
              13.4% 13.1% 16.8% 25.3% 32.8%    
... ... ... ...       5,834 6,015 5,532 5,229 5,488    
              0.144% 0.188% 0.049% -0.020% 0.042%    
... ... ... ...       1,206 1,210 1,000 891 1,108    
... ... ... ...       17.1% 16.7% 15.3% 14.6% 16.8%    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Sanofi-Aventis Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Sanofi-Aventis Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are

Read more »

This Annual Statistical Dossier offers a summary of Sanofi-Aventis Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Sanofi-Aventis Czech Republic at a Glance

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed

Read more »

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines..

This report offers a summary of the Company's performance in 2001-2013. You will find here all the key numbers from the Company's balance sheet, income statement and cash flow and main ratios related to the Company's business

Sanofi-Aventis Czech Republic in Numbers

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed

Read more »

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines..

This excel file offers a summary of the Company's performance in 2004-2013. You will find here all the key numbers from the Company's balance sheet, income statement and cash flow and main ratios related to the Company's business

Sanofi-Aventis Czech Republic made a net profit of CZK 15.2 mil in 2017, down 58.8% when compared to the last year. Total sales reached CZK 7,268 mil, which is up 8.47% when compared to the previous year.

Historically, the company’s

Read more »

Sanofi-Aventis Czech Republic made a net profit of CZK 15.2 mil in 2017, down 58.8% when compared to the last year. Total sales reached CZK 7,268 mil, which is up 8.47% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 73.4 mil in 2005 and an all time low of CZK 1.19 mil in 2014.

In terms of sales, Sanofi-Aventis Czech Republic reached an all time high of CZK 7,525 mil in 2010 and an all time low of CZK 2,128 mil in 2005.

Sanofi-Aventis Czech Republic's net profit has grown -19.5% a year on average in the last five years while sales have increased by 0.118% a year since 2012.

The firm generated its shareholders an average return on invested capital of 2.27% in the last five years.

As far as Sanofi-Aventis Czech Republic's peers are concerned, Bayer Czech Republic posted a net profit and sales of CZK 106 mil and CZK 4,180 mil in 2017 and Amgen Czech Republic generated a net profit of CZK 37.8 mil (with sales of CZK 417 mil).

You can see all the company’s data at Sanofi-Aventis Czech Republic Profile, or you can download a report on the company in the report section.

Sanofi-Aventis Czech Republic made a net profit of CZK CZK 15.2 mil under revenues of CZK 7,268 mil in 2017, down 58.8% and 8.47%, respectively, when compared to the last year.

This translates into a net margin of 0.210%. Historically,

Read more »

Sanofi-Aventis Czech Republic made a net profit of CZK CZK 15.2 mil under revenues of CZK 7,268 mil in 2017, down 58.8% and 8.47%, respectively, when compared to the last year.

This translates into a net margin of 0.210%. Historically, the firm’s net margin reached an all time high of 3.45% in 2005 and an all time low of -0.099% in 2004. The average net margin in the last five years amounted to 0.534%.

On the operating level, EBITDA margin reached 0.536% and EBIT amounted to 0.698% of sales in 2017.

As far as Sanofi-Aventis Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Sanofi-Aventis Czech Republic Profile, or you can download a report on the company in the report section.

Sanofi-Aventis Czech Republic made a net profit of CZK 15.2 mil under revenues of CZK 7,268 mil in 2017, down -58.8% and 8.47%, respectively, when compared to the last year. This translates into a net margin of 0.210%.

Historically,

Read more »

Sanofi-Aventis Czech Republic made a net profit of CZK 15.2 mil under revenues of CZK 7,268 mil in 2017, down -58.8% and 8.47%, respectively, when compared to the last year. This translates into a net margin of 0.210%.

Historically, the firm’s net profit reached an all time high of CZK 73.4 mil in 2005 and an all time low of CZK -2.02 mil in 2004. Since 2012, the firm's net profit has increased -66.3% or -19.5% a year on average.

On the operating level, EBITDA reached CZK 50.7 mil, up 152% when compared to the previous year. Over the last five years, company's EBITDA has grown -8.91% a year on average.

As far as Sanofi-Aventis Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Sanofi-Aventis Czech Republic Profile, or you can download a report on the company in the report section.

Sanofi-Aventis Czech Republic's net debt reached CZK 774 mil and accounted for 103% of equity at the end of 2017. The ratio is up 32.4% when compared to the previous year.

Historically, the firm’s net debt to equity reached

Read more »

Sanofi-Aventis Czech Republic's net debt reached CZK 774 mil and accounted for 103% of equity at the end of 2017. The ratio is up 32.4% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 336% in 2004 and an all time low of 57.8% in 2015.

When compared to EBITDA, net debt amounted to 15.3x at the end of the year. The ratio reached an all time high of 29.5 in 2004 and an all time low of 4.16 in 2005.

As far as Sanofi-Aventis Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 94.4%x and 2.49x when compared to EBITDA at the end of 2017. Amgen Czech Republic ended the year 2017 with a net debt at -0.147%x of equity and -0.006x when compared to its EBITDA while Amgen Czech Republic had net debt at -0.147%x of equity and -0.006x to EBITDA at the end of the year.

You can see all the company’s data at Sanofi-Aventis Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
Sanofi-Aventis CR's net profit fell 58.8% to CZK 15.2 mil in 2017
Sanofi-Aventis CR's net profit fell 58.8% to CZK 15.2 mil in 2017
Sanofi-Aventis CR's employees rose 1.28% to 396 in 2017
Sanofi-Aventis CR's Capital Expenditures rose 5,147% to CZK 110 mil in 2017
Sanofi-Aventis CR's Total Cash From Operations rose 43.2% to CZK -90.1 mil in 2017
Sanofi-Aventis CR's Net Debt/EBITDA fell 46.5% to 15.3 in 2017
Sanofi-Aventis CR's Cash & Cash Equivalents fell 93.9% to CZK 0.719 mil in 2017
Sanofi-Aventis CR's ROCE fell 63.7% to 0.863% in 2017
Sanofi-Aventis CR's Net Margin fell 62.0% to 0.210% in 2017